Tests low-dose aspirin effect on platelets in kidney disease patients
Tests low-dose aspirin with Aranesp on platelet function in adults with kidney failure.
Plain-language title generated from the registry record
Registry title: The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp
Key facts
- Where
- Roskilde, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT04330729, who can take part
Where in Denmark
- Medicinsk afdeling, SUH RoskildeRoskilde, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zealand University Hospital
- Trial code
- NCT04330729
- Record updated
- 25 January 2024
- Original description
The aim of the study is toRead full original descriptionShow less
The Effect of Low-dose Salicylate Treatment on Platelet Function in Patients With Renal Failure Treated With Darbepoetin Alfa
The aim of the study is to
1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of Aranesp®) affects platelet function, and how. 2. To determine whether salicylate treatment changes the effect of EPO (erythropoietin) on platelet function.
Inclusion: Chronic hemodialysis, peritoneal dialysis or CKD 5 treated conservatively; aged 18-85; indication for treatment with Erythropoiesis-stimulating agents (ESA).
Exclusion: Known indication for ASA. If the patient is being treated with ASA, and the physician does not find any indication for this treatment, this can be stopped, and the patient included after 4 weeks; Current anticoagulant therapy, e.g. warfarin, ADP receptor inhibitor (excepting short-term anticoagulant therapy in connection with dialysis); Change in ESA dosis >33,3% within previous 2 month; Known allergy to ASA; Known contraindication to ASA, e.g. recent bleeding episode; Active cancer - except for non-melanoma skin-cancer; Raised reticulocyte count; Fertile women. Pregnancy is excessively rare in dialysis patients. Women who are <50 years, or who are still menstruating will be excluded from the study; Short expected length of life; Inability to give informed consent; Expected non-compliance; Iron deficiency (defined as a reticulocyte Hgb <1,8 fmol. Patients can be included when their iron deficiency has been cured. ; Stable Aranesp ® dose <20 µg/week.